Your browser doesn't support javascript.
The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.
Li, Gen; Zhou, Zhongcheng; Du, Peng; Yu, Meixing; Li, Ning; Xiong, Xinxin; Huang, Hong; Liu, Zhihai; Dai, Qinjin; Zhu, Jie; Guo, Chengbin; Wu, Shanyun; Baptista-Hon, Daniel T; Miao, Man; Ming, Lam Wai; Wu, Yong; Zeng, Fanxin; Zhang, Charlotte L; Zhang, Edward D; Song, Haifeng; Liu, Jianghai; Lau, Johnson Yiu-Nam; Xiang, Andy P; Zhang, Kang.
  • Li G; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Zhou Z; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Du P; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Yu M; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Li N; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Xiong X; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Huang H; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Liu Z; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Dai Q; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Zhu J; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Guo C; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Wu S; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Baptista-Hon DT; University Hospital and Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Macau 030027, China.
  • Miao M; University Hospital and Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Macau 030027, China.
  • Ming LW; University Hospital and Center for Biomedicine and Innovations, Faculty of Medicine, Macau University of Science and Technology, Macau 030027, China.
  • Wu Y; Jinan University First Affiliated Hospital, Jinan University, Guangzhou 510630, China.
  • Zeng F; Department of Clinical Research Center, Dazhou Central Hospital, Dazhou 635099, China.
  • Zhang CL; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Zhang ED; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
  • Song H; Department of Bioinformatics and AI, Bioland Laboratory, Guangzhou 510000, China.
  • Liu J; ABLINK Biotech Co., Chengdu 610000, China.
  • Lau JY; Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong 610051, China.
  • Xiang AP; Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou 510000, China.
  • Zhang K; Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510620, China.
Precis Clin Med ; 4(3): 149-154, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1467398
ABSTRACT
To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Precis Clin Med Year: 2021 Document Type: Article Affiliation country: Pcmedi

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: Precis Clin Med Year: 2021 Document Type: Article Affiliation country: Pcmedi